Cardiotoxicity of breast cancer drug treatments

Breast cancer (BC) is a leading cause of cancer-related mortality among women worldwide. BC is regarded as a systemic disease. Consequently, the majority of BC patients undergo systemic therapy to reduce the risk of distant metastasis (DM) and associated mortality. Although systemic therapies improve patients' outcome, they are associated with significant side effects, particularly cardiotoxicity and cardiovascular complications. Such side effects vary significantly in severity and duration. Cardiotoxicity may remain undetected for years post-treatment until the symptoms of heart failure (HF) present in the patient, which can reduce life expectancy, quality of life, and even lead to death. Therefore, it is vital to investigate the cardiotoxic and cardiovascular risks of BC treatment regimens to identify patients who would benefit most from cardiac monitoring. As it stands, cardiotoxicity is reported from individual studies or for selected drug therapies only. This review fulfils a gap in the literature by combining clinical studies of cardiotoxicity together from clinical trial data published on clinicaltrials.gov.uk.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2025-03-15
DOI
https://doi.org/10.1016/j.tranon.2025.102352
Citations
5
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
6.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cardiotoxicity of breast cancer drug treatments

Corinne L. Woodcock, Emad A. Rakha, Maria Haque, Catrin S. Rutland et al.
5 citations
Translational Oncology
Chemotherapy-induced cardiotoxicity and mitigation
6.94
article

Cardiotoxicity of breast cancer drug treatments

Corinne L. Woodcock, Emad A. Rakha, Maria Haque, Catrin S. Rutland, Alexander Dean, Melissa B. Davis, Jennie N. Jeyapalan, N Atallah, Mansour Abdulaziz Alsaleem, Sheeba Irshad, Dhruvika Varun, Nigel P. Mongan, Anna E. Harris, Rodhan Patke, Jorja Jackson-Oxley, Rachel L Thompson, Cyntholia H Okui
article en
5 citations

Abstract

Breast cancer (BC) is a leading cause of cancer-related mortality among women worldwide. BC is regarded as a systemic disease. Consequently, the majority of BC patients undergo systemic therapy to reduce the risk of distant metastasis (DM) and associated mortality. Although systemic therapies improve patients' outcome, they are associated with significant side effects, particularly cardiotoxicity and cardiovascular complications. Such side effects vary significantly in severity and duration. Cardiotoxicity may remain undetected for years post-treatment until the symptoms of heart failure (HF) present in the patient, which can reduce life expectancy, quality of life, and even lead to death. Therefore, it is vital to investigate the cardiotoxic and cardiovascular risks of BC treatment regimens to identify patients who would benefit most from cardiac monitoring. As it stands, cardiotoxicity is reported from individual studies or for selected drug therapies only. This review fulfils a gap in the literature by combining clinical studies of cardiotoxicity together from clinical trial data published on clinicaltrials.gov.uk.

Translational OncologyVol. 55
University of Nottingham (GB), Qassim University (SA), Guy's and St Thomas' NHS Foundation Trust (GB), Cornell University (US), Institute of Mental Health (GB), Sunny BioDiscovery (United States) (US), Hamad Medical Corporation (QA), Morehouse School of Medicine (US)
Good health and well-being
Openalex Percentile: Top 3%
Chemotherapy-induced cardiotoxicity and mitigation
6.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.